GB201605127D0 - Composition and methods of treatment - Google Patents

Composition and methods of treatment

Info

Publication number
GB201605127D0
GB201605127D0 GBGB1605127.8A GB201605127A GB201605127D0 GB 201605127 D0 GB201605127 D0 GB 201605127D0 GB 201605127 A GB201605127 A GB 201605127A GB 201605127 D0 GB201605127 D0 GB 201605127D0
Authority
GB
United Kingdom
Prior art keywords
treatment
composition
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1605127.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blueberry Therapeutics Ltd
Original Assignee
Blueberry Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueberry Therapeutics Ltd filed Critical Blueberry Therapeutics Ltd
Priority to GBGB1605127.8A priority Critical patent/GB201605127D0/en
Publication of GB201605127D0 publication Critical patent/GB201605127D0/en
Priority to CN201780019759.6A priority patent/CN109562077A/zh
Priority to JP2018545179A priority patent/JP7796465B2/ja
Priority to US16/088,372 priority patent/US12678414B2/en
Priority to PCT/GB2017/050852 priority patent/WO2017163091A1/en
Priority to EP17715266.7A priority patent/EP3432867A1/en
Priority to CN202311073155.3A priority patent/CN117379391A/zh
Priority to JP2023148797A priority patent/JP2023182607A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Optics & Photonics (AREA)
  • Emergency Medicine (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
GBGB1605127.8A 2016-03-25 2016-03-25 Composition and methods of treatment Ceased GB201605127D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB1605127.8A GB201605127D0 (en) 2016-03-25 2016-03-25 Composition and methods of treatment
CN201780019759.6A CN109562077A (zh) 2016-03-25 2017-03-24 组合物和治疗方法
JP2018545179A JP7796465B2 (ja) 2016-03-25 2017-03-24 組成物および治療方法
US16/088,372 US12678414B2 (en) 2016-03-25 2017-03-24 Compositions for treatment of fungal nail infections
PCT/GB2017/050852 WO2017163091A1 (en) 2016-03-25 2017-03-24 Composition and methods of treatment
EP17715266.7A EP3432867A1 (en) 2016-03-25 2017-03-24 Composition and methods of treatment
CN202311073155.3A CN117379391A (zh) 2016-03-25 2017-03-24 组合物和治疗方法
JP2023148797A JP2023182607A (ja) 2016-03-25 2023-09-13 組成物および治療方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1605127.8A GB201605127D0 (en) 2016-03-25 2016-03-25 Composition and methods of treatment

Publications (1)

Publication Number Publication Date
GB201605127D0 true GB201605127D0 (en) 2016-05-11

Family

ID=56027421

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1605127.8A Ceased GB201605127D0 (en) 2016-03-25 2016-03-25 Composition and methods of treatment

Country Status (6)

Country Link
US (1) US12678414B2 (cg-RX-API-DMAC7.html)
EP (1) EP3432867A1 (cg-RX-API-DMAC7.html)
JP (2) JP7796465B2 (cg-RX-API-DMAC7.html)
CN (2) CN109562077A (cg-RX-API-DMAC7.html)
GB (1) GB201605127D0 (cg-RX-API-DMAC7.html)
WO (1) WO2017163091A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710491D0 (en) * 2017-06-30 2017-08-16 Blueberry Therapeutics Ltd Composition and methods of treatment
US12576049B1 (en) 2019-10-08 2026-03-17 Hallux Inc. Onychomycosis treatment methods
JP2022552252A (ja) 2019-10-08 2022-12-15 ハルクス,インコーポレイテッド 爪真菌症治療用組成物及び方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU223343B1 (hu) 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
US20030147925A1 (en) * 1998-09-11 2003-08-07 Samuel P. Sawan Topical dermal antimicrobial compositions, methods for generating same, and monitoring methods utilizing same
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
US9149440B2 (en) * 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
CA2565556A1 (en) * 2004-05-03 2005-12-08 Neosil, Inc. Polycationic antimicrobial therapeutic
WO2007012114A1 (en) 2005-07-25 2007-02-01 Nanotechnology Victoria Pty Ltd Microarray device
US20070249546A1 (en) 2006-04-22 2007-10-25 Sawaya Assad S Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
WO2010011354A2 (en) 2008-07-25 2010-01-28 Innovation Biomedical Devices, Inc. Enchanced trans-keratin drug delivery
AU2010336441B2 (en) 2009-12-23 2015-02-05 Nuvo Research Inc. Highly permeating terbinafine formulation for treating onychomycosis
WO2012092527A1 (en) * 2010-12-29 2012-07-05 Strategic Science & Technologies, Llc Delivery of treatments transdermally for fungal infections and other indications
GB201117538D0 (en) 2011-10-11 2011-11-23 Royal Veterinary College The Methods
EP2664327A1 (en) * 2012-05-14 2013-11-20 Almirall S.A. Topical pharmaceutical compositions comprising terbinafide and urea
US8697753B1 (en) * 2013-02-07 2014-04-15 Polichem Sa Method of treating onychomycosis
GB201317005D0 (en) 2013-09-25 2013-11-06 Blueberry Therapeutics Ltd Composition and methods of treatment
GB201511799D0 (en) 2015-07-06 2015-08-19 Blueberry Therapeutics Ltd Composition and methods of treatment

Also Published As

Publication number Publication date
JP7796465B2 (ja) 2026-01-09
EP3432867A1 (en) 2019-01-30
CN117379391A (zh) 2024-01-12
JP2019509281A (ja) 2019-04-04
US20200206160A1 (en) 2020-07-02
CN109562077A (zh) 2019-04-02
WO2017163091A1 (en) 2017-09-28
US12678414B2 (en) 2026-07-14
JP2023182607A (ja) 2023-12-26

Similar Documents

Publication Publication Date Title
ES3065470T3 (en) Novel micro-dystrophins and related methods of use
ZA202006746B (en) Methods of treatment
SG10202101986UA (en) Tetracycline compounds and methods of treatment
IL258955B2 (en) Cancer treatment preparations and methods
PL3548033T3 (pl) Związki i sposoby ich stosowania
SG11201706767RA (en) Materials and methods for treatment of hemoglobinopathies
PL3212226T3 (pl) Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych
ZA201900960B (en) Methods and compositions for the treatment of cancer
GB201609786D0 (en) Compounds and method of use
ZA201900044B (en) Tuberculosis compositions and methods of treating or preventing tuberculosis
ZA201804380B (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
EP3134108A4 (en) Agents and methods of treatment
ZA201808232B (en) Compositions and methods for the treatment of cancer
GB201511799D0 (en) Composition and methods of treatment
ZA201902155B (en) Compositions and methods for treatment of insulin resistance
HUE068830T2 (hu) Készítmények és módszerek homocisztinuria kezelésére
ZA201900984B (en) Methods and compositions for the treatment of warts
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201621737D0 (en) Compositions and methods of treatment
PT3503885T (pt) Composição farmacêutica e métodos de utilização
DK3313207T3 (en) Compositions and methods for the treatment of malnutrition
GB201503371D0 (en) Methods of screening and treatment
IL261794A (en) Preparations and methods for using them
ZA201802201B (en) Novel formulation and treatment methods
GB201417248D0 (en) Compostion and methods of treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)